peran+perawat+dalam+pencegahan+gagal+ventilasi+pada+pasien+covid+19

Diamond Home Support Extends its Home Cleaning Services Due to High Demand

Rev Up Marketers

Diamond Home Support is a well-established provider of professional home cleaning services in the UK. In the latest development, the company announces an extension of its services due to a significant upward trend in the home cleaning market, underscoring a substantial shift in consumer behavior. As we move towards 2025, the demand for home cleaning services continues to rise, particularly among homeowners under 35, with a remarkable 40% now utilizing home cleaning services regularly. This surge in demand can be attributed to various factors, including the recent shift to remote work and heightened hygiene awareness following the Covid pandemic. Many households have come to view professional cleaning services not merely as luxuries but as essential components of maintaining a healthy and comfortable home environment. With these new developments, Diamond Home Support now offer a wide range of local cleaning services across more of the UK, ensuring that homeowners receive the services they require. With a network of over 200 local offices, Diamond Home Support provides regular house cleaning, end-of-tenancy cleaning, and specialized services like spring cleaning and antiviral sanitation. Their experienced, vetted, and insured cleaners deliver consistent, high-quality services, allowing customers to develop a rapport with the same cleaner for each visit, ensuring their unique needs are met. In addition to cleaning, many of our local offices offer comprehensive home help services, including laundry, bed making, shopping, and companionship. The company understands that maintaining a home goes beyond cleaning, so they also provide gardening services such as grass cutting, weeding, and pruning in select areas. The aim is to enhance the quality of life for their customers by providing reliable and affordable services tailored to their individual requirements. Andrew Watton, Managing Director and Founder of Diamond Home Support, states that the market is witnessing a lasting change in how people prioritize home cleanliness. The trend indicates a growing inclination among younger generations to invest in services that enhance their quality of life, allowing them to reclaim time for leisure and personal interests. In the wake of economic fluctuations and cost-of-living challenges, the home cleaning sector has demonstrated remarkable resilience, with spending on cleaning services increasing by over 50% in the past six years. Andrew emphasizes the need for cleanliness and time savings remains a top priority for many households. Even in challenging economic times, the demand for professional cleaning services continues unabated. As the home cleaning market continues to evolve, Diamond Home Support remains committed to meeting the needs of its customers, providing high-quality cleaning services that enhance the quality of life for families and individuals alike. About the Company - Diamond Home Support Diamond Home Support is one of the largest cleaning franchise operators in the UK, dedicated to providing high-quality cleaning services to homes across the country. With a focus on reliability and customer satisfaction, Diamond Home Support aims to make professional cleaning accessible and convenient for all. The company prides itself on its strong network of franchisees, ensuring that customers receive exceptional service tailored to their individual needs. Contact Details Diamond Home Support Andrew Watton press@diamondhomesupport.com Company Website https://diamondhomesupport.com

October 02, 2024 08:33 AM Eastern Daylight Time

Image

Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines

Benzinga

By Anthony Termini, Benzinga Results of research conducted at Emory University, the University of Wisconsin-Madison and UC Berkeley estimate that more than five million Americans suffering from depression could benefit from psilocybin-assisted therapy. This first-of-its-kind peer-reviewed study is scheduled to be published in the scientific journal Psychedelics on September 24, 2024. How Psilocybin Can Deliver Rapid And Sustained Antidepressant Effects This latest research report is not the first to look into the use of psilocybin to treat depression. There is a body of research showing that it can potentially deliver quick and continuous antidepressant effects. For example, results of randomized clinical trials have been published in the Journal of the American Medical Association and by the University of California San Francisco. In fact, psilocybin’s therapeutic properties had been researched as early as the 1950s by Swiss drugmaker Sandoz Group (OTC: SDZNY) as part of specific psychiatric studies. A Pioneering Drug Development Company Focused On Botanical Therapies All of this seems to support the work of AJNA BioSciences, based in Littleton, Colorado. The company could be strategically poised to lead and create value in this emerging category of pharmaceuticals. AJNA is currently developing a full-spectrum psilocybin “novel antidepressant.” AJNA believes that a standardized botanical medicine made from psilocybin will be in high demand. It reports that in 2020, doctors prescribed nearly $19 billion worth of drugs to treat depression. Researchers have estimated that the market for psychedelic drugs will grow annually by more than 12% through at least 2027. AJNA believes it can capture a high single-digit percentage of that market. What is significant about AJNA’s drug development work is that it is standardizing botanical materials to meet strict FDA guidelines. AJNA reports that it is the first biotech company working with botanicals under a DEA Schedule-1 license. AJNA is developing a daily-use anti-depression treatment through what it intends to be a fully characterized and FDA-approved formulation. AJNA has advanced the development of two prescription drug candidates: its CBD-based Autism Spectrum Disorder drug is anticipating a phase 2 trial in late 2024, and its psilocybin-based antidepressant drug has a phase 1 trial scheduled for early 2025. The company’s research team, led by scientists from Harvard, Johns Hopkins and New York University, is conducting clinical trials in the same manner as large drug manufacturers. However, AJNA is working to transform the pharmaceutical industry by pioneering a new regulatory pathway to produce drugs from plants. Why AJNA Is Focused On FDA Approvals Authors of the research to be published by Emory University, the University of Wisconsin-Madison and UC Berkeley say that their “projections are highly contingent on…precise FDA approval parameters.” In other words, how broadly or narrowly the FDA defines this new class of drugs. AJNA seems to have anticipated some of this. It reports that it has distinguished itself as one of the leaders in the evolving field of botanical drug development and has paid strict attention to how the FDA is defining the pathways for botanical drugs to get approved. Joel Stanley, AJNA’s CEO, says that FDA approval is a critical component of bringing new drugs to market. Federal law requires that a manufacturer show that the drugs they produce are safe and effective. Stanley also notes that without the FDA’s stamp of approval, a drug is unlikely to be considered for reimbursement by health insurance carriers. For botanical drugs to be an accepted component of a physician’s and patient’s routine treatment options, they must be approved by the FDA. AJNA is committed to producing natural botanical drugs that have undergone rigorous laboratory and clinical scrutiny to demonstrate that they deliver “nature, backed by science.” AJNA is currently raising capital in a crowdfunding round through Wefunder. Stanley says that “by investing in AJNA, you’re helping to change the healthcare paradigm to include optionality that none of us have ever had.” With less than a week before the current financing/investment opportunity closes, interested investors can find more information on the Wefunder website. Featured photo by Monika Schröder on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 02, 2024 08:25 AM Eastern Daylight Time

Image

Largest Immersive Gaming Facility in the World Is Now Open at Toronto’s Stockyards

Activate

Activate, the world’s first active gaming facility and viral sensation on TikTok, is thrilled to announce the opening of its largest location in the world, situated in Toronto's vibrant Stockyards district. The new facility, located at 30 Weston Rd, Unit C209, promises an unparalleled entertainment experience that blends cutting-edge technology with physical activity. Activate Stockyards boasts an impressive facility spanning 19,218 square feet, making it the largest of its kind in the region. This expansive venue houses 19 unique game rooms, including the TikTok famous Mega Grid, adrenaline-fueled Lasers, Push with 452 light-up buttons and the precision-driven Strike, all designed to deliver a distinct and thrilling experience. The sheer size and vast selection of game rooms offer visitors plenty of space to engage in a wide range of interactive and immersive adventures. ”We are thrilled to be bringing Activate's largest location in history to Canada’s largest city, Toronto,” proclaimed Adam Schmidt, Founder & CEO of Activate. “This exciting new location is a fantastic addition to the vibrant Stockyards neighborhood. We can't wait for Toronto’s bustling community to experience the largest entertainment concept in the world.” Activate is taking over the immersive gaming world, now dominating 40 locations across the United States and Canada, and it shows no signs of slowing down. As the first active gaming facility to become a TikTok sensation, Activate has built a social media empire, captivating millions with its innovative, interactive experiences. Their unique approach to active gaming has set them apart, cementing their position as a leader in the entertainment world. Internationally, Activate is expanding with a new Dubai location and a UK debut in December 2024. For a sneak peek into Activate’s dynamic gaming experience, click here. Join the Inner Circle to be the first to hear about new locations, behind-the-scenes information, deals, and more. Please find imagery assets here. Activate is the world’s first active gaming experience where players #EnterTheGame. Activate offers a unique blend of physical activity and gaming that promotes a healthy lifestyle. Each Activate location provides fun and interactive rooms for players to compete, earn stars and track achievements. With the global headquarters located in Winnipeg, Canada, Activate has grown to 30 locations across Canada, the U.S. and now the world! To join the active gaming movement, visit playactivate.com. Follow Activate on social media: Facebook: Activate Instagram: @activategames TikTok: @activategames Contact Details Jive PR + Digital Jalila Singerff +1 613-614-6777 jalila@jiveprdigital.com Company Website https://playactivate.com

September 23, 2024 08:00 AM Eastern Daylight Time

Buffet Shifts To Cash, DoJ Launches Nvidia Investigation – Is It Time To Invest In Gold And Other Stores Of Value?

Benzinga

By Austin DeNoce, Benzinga Get your hands on gold with an IRA or delivered to your door with Preserve Gold! As market volatility surges and concerns over a potential U.S. recession intensify, investors are increasingly looking for a store of value to help protect their assets. Recent events, including a significant rise in the VIX and a Department of Justice (DoJ) investigation into the market darling Nvidia (NASDAQ: NVDA), have amplified fears of a broader market downturn. Adding to these concerns is renowned investor Warren Buffett’s decision earlier this year to increase his cash position by selling a large portion of his Apple (NASDAQ: AAPL) stake, signaling caution in one of the most experienced market players. With these developments unfolding, gold seems to be emerging as a compelling investment. Here’s why investors might consider adding gold to their portfolios. Rising Volatility And Market Concerns The volatility index (VIX), which measures expected volatility in the S&P 500 over the next month, has recently soared to levels not seen since the COVID-19 pandemic. This surge, driven by a dramatic 12% decline in Japan's Nikkei index and a subsequent global asset selloff, resulted in the VIX experiencing a record single-day increase of 181 points. Even surpassing levels observed during the 2008 financial crisis, this spike demonstrated the heightened bearish sentiment across global markets. The VIX futures market remains in backwardation, indicating that investors expect elevated volatility to persist in the short term. Amid this backdrop, speculative positioning in VIX futures suggests that some investors may be preparing for further market turbulence, despite recent adjustments indicating a potential shift toward more cautious, net-long positions. Additionally, while there have been some positive economic indicators, such as a strong ISM services report, weak manufacturing and employment data, combined with a lack of clear signals from the Federal Reserve about emergency rate cuts, have kept market sentiment tentative. DoJ Investigation Into Nvidia A recent antitrust investigation by the Department of Justice (DoJ) into Nvidia, a key driver of market gains earlier this year, has added another layer of uncertainty. In September, Nvidia experienced a massive $279 billion decline in market capitalization, one of the largest single-day drops in history. The DoJ's probe focuses on potential anti-competitive practices, including exclusive chip usage penalties and restrictions on supplier switching. While Nvidia has defended its business practices, emphasizing its long history of lawful innovation and accessibility, investor confidence seems to have been shaken. Concerns about slowing growth rates, coupled with seasonal vulnerabilities in September – a month historically challenging for stocks – have exacerbated these fears. As a result, a market heavily skewed toward tech investments has become increasingly vulnerable to negative news, prompting a reassessment of investment strategies among many market participants. Warren Buffett’s Shift To Cash Against this backdrop of rising volatility and heightened scrutiny of markets, Warren Buffett’s decision to reduce his stake in Apple and increase Berkshire Hathaway’s (NYSE: BRK.B) cash position further underscores the validity behind investor caution. Between December 2023 and June 2024, Berkshire Hathaway cut its Apple holdings by 55%, a move that surprised many, given Apple's strong revenue performance. This decision appears to reflect concerns about Apple's valuation and the potential challenges it faces in the Chinese market. Buffett’s shift to cash, a rare move for the Oracle of Omaha, signals a strategic recalibration in response to current market conditions. Despite his reduction in Apple shares, Buffett remains bullish on Berkshire Hathaway, having repurchased $5 billion of its shares recently. This suggests that, while Buffett sees value in his company’s diversified business model, he is wary of broader market risks and is positioning his portfolio defensively in anticipation of potential downturns. Is It Time To Consider Gold? Given these developments, investors may want to consider gold as a store of value in uncertain times. Gold has continued to make gains in 2024, marking the latest in a string of all-time highs in August – proving its resilience throughout heightened market drawdowns. As concerns over market volatility, regulatory scrutiny and a potential recession grow, gold’s historical role as a hedge against economic uncertainty has proven increasingly attractive amid a turbulent geopolitical landscape. For those looking to diversify their portfolios with gold, Preserve Gold offers a range of services to facilitate gold investments. The company provides transparent, client-focused service, including secure shipping, hassle-free buyback options, free, insured shipping and price matching to ensure competitive value. Preserve Gold is dedicated to continuous customer education, with a team of Precious Metals Specialists dedicated to assisting clients. With a focus on transparency and a reputation for reliability, Preserve Gold could be an ideal partner for those looking to add gold to their investment strategy and protect their portfolio. Get your hands on gold with an IRA or delivered to your door with Preserve Gold! Featured photo by Zlaťáky.cz on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 20, 2024 08:50 AM Eastern Daylight Time

Image

SBC Medical Group Holdings (Nasdaq: SBC) Claims First-Mover Advantage In Medical Services Franchise Model, Debuts On Nasdaq

Benzinga

By Gerelyn Terzo, Benzinga While it’s hard to put a price tag on time, it’s one of those commodities that healthcare professionals value highly. And yet, many physicians, including surgeons, are mired in administrative work, costing them valuable time that they could otherwise be spending on patient care. Fortunately, the medical field continues to see new innovations such as AI-powered diagnostics, surgery robots, wearables — and the rise of service organizations that shoulder the weight of otherwise mundane administrative tasks. As a result, healthcare professionals across medical segments have more options than ever to keep their operations running smoothly while optimizing performance. One company in the vanguard of this trend is SBC Medical Group Holdings (NASDAQ: SBC), a Tokyo-based medical services healthcare company with a history in the aesthetics space that specializes in solving the problems of medical care providers. SBC has its roots in providing management services to cosmetic treatment centers in Japan, an industry where demand is on the rise, fueled by procedures such as dermal fillers, botulinum toxin (botox) and eyelid surgery and more. Bringing A New Business Model To The Aesthetic Medical Industry SBC Medical’s business model brings the franchisee-franchisor model to a new industry. This model is one that is appreciated by many investors for its proven success in sectors like restaurants and now in healthcare, including medical clinics. SBC believes that as the pioneer of the franchise model in the global aesthetics medical industry, it enjoys a first-mover advantage. The company boasts a No. 1 leading position in Japan’s growing aesthetics medical industry, reporting that it generates stable and high-profit margins owing to the collection of ongoing franchise fees. This model involves franchisor-franchisee contracts or agreements between any of SBC ’s Japanese subsidiaries and medical corporations serving as the umbrella for a total of 218 clinic treatment centers in Japan, with 2 additional clinics located outside of the country. These beauty clinics, which operate under the Shonan Beauty Clinic brand, specialize in services ranging from breast augmentation and laser hair removal to cosmetic dental procedures and beyond. The administrative tasks associated with providing these kinds of medical services can be burdensome without proper support. Supporting Healthcare Professionals Through Management Services The comprehensive management services that SBC provides to franchise clinics run the gamut. Depending on the practice’s needs, SBC might handle its IT requirements, advertising and marketing needs (such as operating social media channels), hiring, payroll, reservations, staff housing and other such requirements. Additionally, SBC supports franchisee clinics in other ways, extending to the construction and design of clinics, procurement and resale of medical equipment and consumables, the provision of cosmetic products to patients, licensure/IP, customer loyalty programs and more. A common thread across these services is that they represent time-consuming activities that can take a toll on practice owners, interfering with their ability to give 100% of their attention to providing high-quality care to their patients. While the services may vary, the end goal is the same - to create greater efficiencies for the medical practice while saving healthcare professionals valuable time and streamlining their operations. As a result, the doctors can focus on what they do best - caring for patients. Importantly, SBC is not limited to any single medical specialization or jurisdiction. Since its inception, the company has expanded its footprint to provide high-quality services to medical corporations overseas, including its first clinic in Vietnam and the United States, respectively. SBC has just made its debut as a publicly traded company on the Nasdaq, giving investors an opportunity to participate in its growing total addressable market. Company And Market Dynamics SBC specializes in providing comprehensive management services to franchisee healthcare clinics. Incorporated in 2023, SBC believes it is well-respected in the industry, owing to the SBC management team’s two decades-plus of industry experience. For more than two decades, SBC CEO and Chairman Dr. Yoshiyuki Aikawa has been at the helm of Aikawa Medical Group, now known as SBC. He also served as president and director of the Japanese Society of Aesthetic Plastic Surgery, Harvard Medical School, PGA. SBC Chief Operating Officer Yuya Yoshida is a seasoned capital markets executive, with former stints at Rakuten Group Co, where he specialized in M&A at Mitsubishi UFJ Financial Group. With a combined 166 franchise clinics, SBC has already claimed the title of Japan’s biggest aesthetic medical group. While the company is in the midst of an expansion push, Japan is its maiden market, where it reports it has a demonstrated track record of success. It plans to continue to grow in Japan while pursuing new growth opportunities in the U.S. and Southeast Asia. Japan’s cosmetic surgery market has experienced steady growth. It is predicted to expand at a compound annual growth rate (CAGR) of 8.1% in the decade leading up to 2033 for a value of $41.6 billion, up from $19 billion in 2023. Meanwhile, the country’s medical aesthetics market was worth $2.6 billion as of last year and is growing at a CAGR of 13% in the current decade for a value of $9 billion by 2033. SBC’s Balance Sheet Investors who are interested in participating in the company’s growth story may find SBC ’s fundamentals interesting. For the fiscal year ended December 31, 2023, SBC’s revenues increased 11% to $193 million with EBITDA of $82 million and net income of $39 million. Revenues increased 27.72% to approximately $54.8 million with a net income of approximately $18.7 million for the three months ended March 31, 2024. The company has a balance sheet to help support its growth, with approximately $96 million in cash and cash equivalents as of March 31, 2024. SBC is not only providing quality comprehensive management services to medical corporations and expanding its Shonan Beauty Clinic brand but doing so profitably. SBC Medical Group Holdings began trading on the Nasdaq under the ticker symbol SBC on September 18 following a business combination with Pono Capital Two (Nasdaq: PTWO), a special purpose acquisition company (SPAC). Investors who would like to participate in SBC’s growth story now have the unique opportunity to do so in the stock’s early days of trading on the Nasdaq market. Featured photo by Bru-nO on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 20, 2024 08:25 AM Eastern Daylight Time

Image

The worst metro areas for job destruction in 2024

Profit Duel

Experts at ProfitDuel conducted a comprehensive analysis of job destruction across the United States, focusing on metro areas that have experienced the most significant employment losses, including business closures. Using data from the U.S. Census Bureau, they identified the regions most impacted by job destruction. 1. New York - Newark - Jersey City New York - Newark - Jersey City has experienced significant job losses, with 1,699,128 jobs destroyed, driven by the high cost of living, the impact of the COVID-19 pandemic, and the shift towards remote work. Many businesses have either downsized or shut down completely, leading to a substantial reduction in employment opportunities. The hospitality, retail, and office sectors have been particularly hard hit, with 52,159 job losses in the food services industry. 2. Los Angeles - Long Beach - Anaheim Los Angeles - Long Beach - Anaheim ranks as the second worst area for job destruction, with 1,072,714 jobs lost. The entertainment and tourism industries, which are vital to the region's economy, faced severe disruptions during the pandemic. The study revealed that there has been 21,801 job destruction in the arts, entertainment, and recreation sector in this metro. Additionally, the high cost of real estate and operational expenses have forced many small and medium-sized businesses to close their doors permanently. 3. Chicago - Naperville - Elgin Chicago - Naperville - Elgin comes in third in terms of job destruction, with 676,970 jobs lost. The decline in manufacturing jobs, with 12,001 jobs lost in this industry alone, coupled with economic challenges faced by the retail and service sectors, has led to significant job losses. The shift to e-commerce has also negatively impacted traditional brick-and-mortar stores in the area. 4. Dallas - Fort Worth - Arlington Dallas - Fort Worth - Arlington has seen considerable job destruction, with 521,722 jobs lost, particularly in the energy sector. The fluctuating oil prices and the transition to renewable energy sources have resulted in layoffs and business closures. The metro area is also dealing with the aftermath of the COVID-19 pandemic, which has affected various industries, including hospitality and retail. 5. Washington- Arlington-Alexandria The Washington - Arlington - Alexandria metro area has not been immune to job destruction, with 487,619 jobs lost. Government budget cuts, the shift to remote work, and the pandemic's impact on local businesses have contributed to employment losses. The hospitality and service industries have been particularly affected, with many establishments closing permanently. 6. Houston - The Woodlands - Sugar Land Houston - The Woodlands - Sugar Land has faced job destruction, with 474,285 jobs lost, primarily due to the volatility in the energy sector. The oil and gas industry's downturn has led to layoffs and company closures. Additionally, the pandemic's impact on the hospitality and retail sectors has exacerbated the job losses in the region. 7. San Francisco - Oakland - Berkeley San Francisco - Oakland - Berkeley has experienced significant job destruction, with 469,641 jobs lost, due to the high cost of living and the tech industry's shift to remote work. Many businesses have relocated to more affordable areas, leading to job losses in the region. The hospitality and retail sectors have also struggled to recover from the pandemic's effects. 8. Philadelphia - Camden Wilmington Philadelphia - Camden - Wilmington has seen notable job destruction, with 457,451 jobs lost, particularly in the manufacturing and service industries. The decline in traditional manufacturing jobs and the pandemic's impact on small businesses have led to significant employment losses. The region is also grappling with the shift to remote work and e-commerce 9. Boston - Cambridge - Newton Boston - Cambridge - Newton ranks among the worst metro areas for job destruction, with 420,746 jobs lost. The high cost of living, the shift to remote work in the tech and education sectors, and the pandemic's impact on local businesses have all contributed to job losses. The hospitality and retail industries have been hit particularly hard. 10. Miami - Fort Lauderdale - Pompano Beach Miami - Fort Lauderdale - Pompano Beach has faced job destruction, with 415,520 jobs lost, primarily due to the downturn in the tourism and hospitality industries. The pandemic severely impacted these sectors, leading to business closures and layoffs. Additionally, the high cost of living and operational expenses have made it difficult for many businesses to survive. Contact Details Profit Duel Mauricio Garcia +1 929-432-8788 support@profitduel.com Company Website https://www.profitduel.com/

September 19, 2024 09:18 AM Eastern Daylight Time

Image

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

MIRA Pharmaceuticals, Inc.

By Meg Flippin, Benzinga MIRA Pharmaceuticals (NASDAQ: MIRA), the pre-clinical-stage pharmaceutical company focused on transforming the treatment of neuropathic pain and mental health disorders through scientific research and technological advancements, is making progress in its clinical development planning for Ketamir-2, its novel oral ketamine analog. So much so that the company said that, as part of its strategic development plan, it’s prioritizing early demonstration of Ketamir-2’s clinical efficacy. That could come as early as 2025 through innovative phase 1/2 study designs. What’s more, the company said it's on track for Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA) in December 2024. "Our primary goal is to demonstrate efficacy in humans as quickly as possible," says MIRA Pharmaceuticals chairperson and CEO Erez Aminov. "By implementing specific study designs and leveraging our ongoing preclinical research, we aim to gather early evidence of clinical benefits, positioning our treatment as a transformative option for neuropathic pain." To bolster its approach to clinical and regulatory approval, MIRA said it brought on a consultant with expertise in navigating academia and regulatory bodies, including the Federal Drug Administration. The company said this addition demonstrates that it is serious about meeting the highest standards in clinical development and regulatory compliance. Ketamir-2’s Approach To Fighting Neuropathic Pain and Depression Ketamir-2 is an oral ketamine analog designed to be taken as a pill. It is being investigated for the treatment of neuropathic pain, treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDDSI) and PTSD. Unlike traditional ketamine, which requires intravenous administration, posing accessibility and safety challenges, Ketamir-2 could potentially simplify and improve the treatment experience. The company is exploring Ketamir-2's potential efficacy in treating chemotherapy-induced depression, cancer-related neuropathic pain and diabetic neuropathy. These conditions often have limited treatment options and significant patient populations needing effective therapies. Neuropathic pain alone is a big market, poised to reach over $14 billion by 2034, growing at a CAGR of 5.7% from now until then. Driving demand for drugs to relieve pain is an aging population in the U.S. and an increase in chronic diseases. Collaborating To Speed Time To Market To get testing underway, MIRA Pharmaceuticals said it is collaborating with Formulex, a nano-technology-based drug delivery company, to develop ways to deliver Ketamir-2. The two focus on a spray-dry based granulation of Ketamir-2 in capsules for clinical studies, optimizing the formulation for improved oral bioavailability and patient convenience. A deterrent to more people using ketamine to treat mental health issues and chronic pain is the delivery. Traditional ketamine treatment for depression requires a Risk Evaluation and Mitigation Strategy (REMS) protocol due to its potential for abuse and severe side effects. This involves strict regulations, including requiring intravenous administration under medical supervision, making it less accessible and more costly for patients. In contrast, Ketamir-2, as an oral formulation, aims to provide a more convenient and less intimidating treatment option. By reducing the need for medical supervision and hospital visits, MIRA Pharmaceuticals says Ketamir-2 could enhance patient compliance and decrease overall treatment costs. Phase I Trial Kicking Off Soon Through the phase I/II study designs MIRA is focused on demonstrating the clinical activity in treating neuropathic pain and potentially other neurologic conditions. The idea is to gather data that can drive faster decision-making and potentially expedite patient access, the company said. The phase 1 clinical trial is slated to kick off in the first quarter of 2025 and will be used to assess safety, tolerability and pharmacokinetics in humans. MIRA says that lays the groundwork for subsequent efficacy studies. MIRA collaborates with international academic research institutes to refine and enhance its clinical development strategy. “We are excited to move smoothly forward with our IND-enabling pre-clinical studies towards Phase I trials, which are designed to provide critical insights into the safety and pharmacokinetic profile of our candidate,” said Dr. Angel, chief scientific advisor at MIRA Pharmaceuticals. “This trial is a pivotal step in our journey to bring novel treatment options for neuropathic pain to patients, and we are committed to executing it with the highest scientific and regulatory standards.” Featured photo by Towfiqu barbhuiya on Unsplash. MIRA Pharmaceuticals, Inc., is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. We hold exclusive license rights in the U.S., Canada and Mexico for Ketamir-2, a novel, patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (“TRD”), major depressive disorder with suicidal ideation (MDSI), and potentially post-traumatic stress disorder (“PTSD”). The statements of the Company's management related thereto contains "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2 and MIRA-55. Any forward-looking statements are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in Annual Report on Form 10-K for the year ended December 31, 2023 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Michelle Yanez +1 305-340-8988 Myanez@mirapharma.com Company Website http://www.mirapharmaceuticals.com/

September 19, 2024 09:00 AM Eastern Daylight Time

Image

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

BEVEL, THE AWARD-WINNING MEN’S GROOMING BRAND SUPPORTS INVEST FEST ENTREPRENEURS WITH $25,000 GRANT

Bevel

Atlanta-based, leading men’s head-to-toe grooming brand Bevel, is proud to present a $25,000 business grant to marketplace vendor Double Dutch Aerobics. Invest Fest is a first of its kind, in-person experience that combines investing, entrepreneurship, pop culture, and entertainment in a festival setting. The festival is where commerce and culture meet at a unique intersection for the empowerment of our community. Bevel is proud to support the community and this innovative fitness program. As the official grooming partner of the 4th annual Invest Fest, Bevel, selected the pioneering fitness business Double Dutch Aerobics, founded by Double Dutch World Champion Michelle Clark and Sean Clark, Master Double Dutch Aerobics Instructor, from over 300+ conference vendors. Double Dutch Aerobics, is also based in Atlanta, Georgia. Founded in 2013 by Tristan Walker, an entrepreneur who identified a need in shaving products and tools for himself and other men like him, Bevel was born from Black entrepreneurship and ingenuity. A decade later, Bevel has revolutionized grooming industry standards and offers a range of premium hair, beard, shave, skin, and body care products that prioritize the needs of Black and brown men. Furthermore, the Atlanta-based brand remains committed to looking for opportunities to best serve its customer and its community. Bevel CEO, Damon Frost, announced the grant donation on the Monday, September 9 th, 2024 episode of Earn Your Leisure’s Market Mondays Podcast. Under the Earn Your Leisure Network, Invest Fest is a premier event focused on financial empowerment and entrepreneurialism. Held on August 23 rd – 25 th 2024 in the Georgia World Conference Centre, the conference included presentations, panels and workshops on investing, entrepreneurship, pop culture and entertainment. The festival-style event enables attendees to network with industry trailblazers, connect with other business owners and even pitch their business ideas for grants. Headquartered in Atlanta, Bevel’s partnership with Invest Fest is a continuation of the brand’s track record of serving its customer and its community through giveback initiatives. The 3-day conference equips many in the community with tools to grow and expand their financial wellness and entrepreneurial ventures. “At Bevel, we are committed to serving our customers with product solutions to address their unique grooming needs and through giveback initiatives that we believe make a real impact in the community,” said Bevel Marketing Leader Breann Davis. “We are grateful to Rashad, Troy and the entire Invest Team for allowing us to partner with amazing companies like Double Dutch Aerobics and elevate the next generation of entrepreneurs who share our commitment to the community.” Bevel products, razors and trimmers are available on www.getbevel.com, Amazon.com, Ulta.com and ULTA Beauty stores, Target.com and Target stores, Walmart.com and select Walmart stores. About Walker & Company Brands Walker & Company Brands, recently acquired by Procter & Gamble, is a family of brands designing health and beauty solutions for people of color. Our vision is to build the world's most consumer-centric health and beauty products company, inspiring unprecedented customer loyalty. With the introduction of the first brand Bevel, Walker & Company launched in 2013. Bevel provides grooming products for Black men, including a full Skin Care regimen, a Shave System, and the Bevel Trimmer, and services designed to help reduce skin irritation and razor bumps. To learn more about Walker & Company Brands, visit www.walkerandcompany.com. About Overtime Elite Overtime Elite is an eight-team league with teams based in Atlanta and other cities around the country. The teams feature some of the top 17-19 year old basketball players globally, both professional and amateur. OTE, owned and operated by Overtime, brings fans as close as possible to the action through broad digital distribution on social accounts with nearly 100 million followers and a streaming deal on Amazon Prime Video. OTE provides two paths - a professional, salaried path and a scholarship path for amateurs, and every player gets the same access to world-class coaching, state-of-the-art training facilities and integrated data and analytics, in addition to a rigorous and customized academic program at OTE Academy. OTE is sponsored by adidas, Bevel, Gatorade, GMC, State Farm and Topps. Contact Details First and Last PR +1 201-569-2080 Bevel@firstandlastpr.com Company Website https://getbevel.com

September 18, 2024 09:10 AM Eastern Daylight Time

Image

1 ... 8 9 10 11 12 ... 513